EDEM3 / ER degradation-enhancing alpha-mannosidase-like protein 3 · IHC design guide

Design Immunohistochemistry for EDEM3

Plan chromogenic EDEM3 IHC in paraffin sections using the cytoplasmic tissue pattern (HPA tissue IHC) and ER-lumen molecular location (UniProt). Compare high-staining adrenal glandular cells with vaginal squamous epithelium, where staining was not detected (HPA tissue IHC), using the catalog antibody’s 2–5 μg/ml IHC range (datasheet A10297-2).

Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use

Immunohistochemistry protocol sheet for EDEM3 (IHC for EDEM3): expected localisation Cytoplasmic staining (HPA tissue IHC); ER lumen (UniProt), antibody A10297-2, validated IHC image, and IHC protocol steps — Printable **EDEM3** IHC protocol sheet — expected localisation Cytoplasmic staining (HPA tissue IHC); ER lumen (UniProt), antibody A10297-2, controls and protocol steps. Open the full EDEM3 IHC guide →

Navigate to: Protocols Staining pattern Controls Antibodies

EDEM3 Immunohistochemistry Experimental Design Guide

Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before staining

	Expected localisation	Cytoplasmic staining (HPA tissue IHC); ER lumen (UniProt)
	Staining pattern	Cytoplasmic staining in most tissues (HPA tissue IHC)
	Antigen retrieval	EDTA pH 8.0 HIER, heat-mediated (datasheet A10297-2)
	Positive control ⓘ	Adrenal gland+4 more · see all
	Negative control ⓘ	Vagina

Important caveats

Reasons your staining may differ from the expected pattern.

	Fixation	Keep fixation consistent across sections (standard IHC practice; not target-specific)
	Caveat	Staining has medium consistency with RNA data (HPA tissue IHC)
	Regulation	Expression regulation unreported (UniProt)
	Isoform / epitope	2 isoforms; mature chain starts at residue 42; epitope unknown (UniProt)

Section 1

Recommended EDEM3 IHC & IF Protocols

The catalog antibody protocol is accompanied by published EDEM3 IHC methods for human white adipose tissue (PMC9535382) and mouse glomerular sections (PMC7782535).

Recommended immunohistochemistry (IHC-P) protocol parameters
Sample	Paraffin-embedded human appendiceal adenocarcinoma tissue; fixative not specified (datasheet A10297-2)
Fixation	Image fixative and duration unreported (datasheet A10297-2); verify before use.
Sectioning	4–5 µm sections on charged slides (standard)
Deparaffinisation	Xylene, graded ethanol series to water (standard)
Antigen retrieval	Heat retrieval: EDTA pH 8.0 (datasheet A10297-2); 20 min, 95–100 °C (standard)
Peroxidase block	3% H2O2, 10 min, room temperature (standard)
Blocking	10% goat serum (datasheet A10297-2)
Primary antibody	Rabbit anti-EDEM3, 2-5 μg/ml (datasheet A10297-2)
Primary incubation	Overnight at 4 °C (datasheet A10297-2)
Detection	Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A10297-2)
Counterstain	Hematoxylin, blue, dehydrate and mount (standard)
Expected result	EDEM3-positive staining in glandular cells of adrenal gland (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic expression in most tissues. No signal in the no-primary control.

💡Decision noteStart IHC-P optimization with heat-mediated EDTA retrieval at pH 8.0 (datasheet A10297-2).

Section 2

What Is the Expected EDEM3 Staining Pattern?

EDEM3 resides in the endoplasmic reticulum lumen and has no transmembrane segment (UniProt Q9BZQ6 topology). In paraffin section IHC, expect cytoplasmic staining in many tissues, especially adrenal and parathyroid glandular cells, cortical neurons, cardiomyocytes, skeletal myocytes, and stomach glandular cells (HPA: High; cytoplasmic expression in most tissues). HPA rates the tissue pattern Approved, with medium consistency against RNA data and external verification pending (HPA: tissue IHC).

What am I looking at on my slide?
Cytoplasmic signal in the listed High cell populations, with little nuclear staining.	This agrees with HPA tissue IHC and the ER location supported by UniProt and HPA ICC-IF. Chromogenic IHC may show a broad cytoplasmic pattern; it need not resolve the ER network (general IHC practice). Judge the named cell populations against neighboring structures on the same section.
Predominantly nuclear, surface, or extracellular staining.	That distribution conflicts with the ER lumen assignment (UniProt Q9BZQ6 topology; HPA: ER localization approved). Treat it as suspect rather than evidence of EDEM3 relocalization. Review morphology, staining controls, and detection background before interpreting any residual cytoplasmic signal (general IHC practice).
Strong signal in a cell population reported as Low or Not detected.	Squamous epithelial cells of the vagina are Not detected, while esophageal squamous epithelial and bladder urothelial cells are Low in the supplied HPA tissue IHC record. Unexpected staining can reflect cross-reactivity or endogenous detection activity (general IHC practice); a single discrepant section cannot establish which cause applies.
Haze across tissue, stroma, or the whole section without a clear cellular pattern.	Diffuse background obscures the expected cytoplasmic distribution (HPA: cytoplasmic expression in most tissues). Consider nonspecific binding, incomplete blocking or washing, and endogenous detection activity as general IHC causes. Compare a control lacking primary antibody before assigning the haze to EDEM3 (general IHC practice).
No discernible signal in a well-preserved, expected-positive cell population.	Absent staining in, for example, adrenal glandular cells or cardiomyocytes conflicts with their High HPA IHC levels. Check the run and tissue morphology before calling the sample negative (general IHC practice). HPA's Approved rating has medium RNA consistency and pending external verification, so its levels are guides rather than guarantees (HPA: tissue IHC).

💡Expected EDEM3 appearanceCall a result positive when cytoplasmic staining is clear in a High HPA cell population, such as adrenal glandular cells or cardiomyocytes; dominant nuclear staining or similarly strong staining in HPA Not detected vaginal squamous cells is suspect (HPA: tissue IHC; UniProt Q9BZQ6 topology).

How each factor affects the staining
Cell population and tissue	HPA reports High staining in six listed tissue and cell pairings, Medium in adipocytes and appendix glandular cells, Low in several other populations, and Not detected in vaginal squamous cells (HPA: tissue IHC). Score the relevant cell type rather than assigning one expectation to an entire section.
Intracellular location	The mature protein is assigned to the ER lumen and lacks a transmembrane segment (UniProt Q9BZQ6 topology); HPA ICC-IF independently assigns an approved ER location. Paraffin chromogenic IHC supports assessment of cytoplasmic staining, but fine ER localization is better judged on the separate IF/ICC guide (general microscopy practice).
Antibody validation	Two listed HPA antibodies, HPA025754 and HPA025755, have Approved IHC status; the supplied record does not label either IHC result Enhanced (HPA: antibody validation). HPA describes the tissue pattern as having medium RNA consistency with external verification pending, so prioritize controls when a pattern is unexpected.
Protein processing and isoforms	UniProt lists a signal peptide at residues 1–41, a mature chain at 42–932, and two isoforms (UniProt Q9BZQ6). The payload gives no antibody epitope or isoform-specific IHC evidence; these annotations alone cannot predict which form the catalog antibody detects.

Why is my staining missing, weak or wrong?
Situation	Likely cause	Next action
A known-positive control tissue has no cytoplasmic signal.	The run, detection reagents, or antibody conditions may have failed (general IHC practice); the selected cell population should be High in the supplied HPA record.	Confirm the expected cell type and preserved morphology, then check control performance, reagent preparation, and the catalog antibody's IHC-P instructions (general IHC practice; HPA: High cell populations).
The result is chiefly nuclear or extracellular.	The distribution conflicts with ER lumen localization (UniProt Q9BZQ6 topology; HPA: ER approved); nonspecific signal or a detection artifact is possible (general IHC practice).	Inspect a control lacking primary antibody, compare cellular morphology, and score only reproducible cytoplasmic staining in the expected cells (general IHC practice; HPA: tissue IHC).
Background is diffuse or remains in a control lacking primary antibody.	Endogenous detection activity or secondary reagent background may contribute; neither pattern establishes EDEM3 staining (general IHC practice).	Use detection-system-appropriate endogenous activity blocking, review secondary reagent specificity, and improve washing or blocking as indicated by the control (general IHC practice).
Vaginal squamous cells stain strongly.	HPA reports this cell population as Not detected; cross-reactivity, detection background, or sample variation needs investigation (HPA: vaginal squamous cells; general IHC practice).	Compare expected-positive tissue and a control lacking primary antibody in the same run; assess whether staining is truly cytoplasmic before interpreting the discrepancy (general IHC practice).
Expected-positive cells stain weakly while background is low.	Weak signal may reflect assay conditions, though HPA High is an observed tissue level and does not guarantee every section will stain strongly (HPA: tissue IHC; general IHC practice).	Verify tissue and cell identity, then follow the catalog antibody's IHC-P guidance when reviewing retrieval, antibody dilution, and detection conditions (general IHC practice).
A cytoplasmic result appears inconsistent across tissues.	HPA levels vary by cell population, and its Approved tissue pattern has medium consistency with RNA data and external verification pending (HPA: tissue IHC).	Score each named cell population against its own HPA level, document controls and morphology, and seek independent confirmation for a consequential discrepancy (general IHC practice; HPA: tissue IHC).

Source: UniProt Q9BZQ6 Human Protein Atlas tissue Human Protein Atlas subcellular

Experiment evidence

IHC & IF images showing EDEM3 staining

IHC analysis of EDEM3 using anti-EDEM3 antibody (A10297-2). EDEM3 was detected in a paraffin-embedded section of human appendiceal adenocarcinoma tissue. Heat mediated antigen retrieval was performed in EDTA buffer (pH 8.0, epitope retrieval solution). The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 2 μg/ml rabbit anti-EDEM3 Antibody (A10297-2) overnight at 4°C. Biotinylated goat anti-rabbit IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The tissue section was developed using Strepavidin-Biotin-Complex (SABC) (Catalog # SA1022) with DAB as the chromogen.

A10297-2 · IHCIHC analysis of EDEM3 using anti-EDEM3 antibody (A10297-2). EDEM3 was detected in a paraffin-embedded section of human appendiceal adenocarc

IHC analysis of EDEM3 using anti-EDEM3 antibody (A10297-2). EDEM3 was detected in a paraffin-embedded section of human liver cancer tissue. Heat mediated antigen retrieval was performed in EDTA buffer (pH 8.0, epitope retrieval solution). The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 2 μg/ml rabbit anti-EDEM3 Antibody (A10297-2) overnight at 4°C. Biotinylated goat anti-rabbit IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The tissue section was developed using Strepavidin-Biotin-Complex (SABC) (Catalog # SA1022) with DAB as the chromogen.

A10297-2 · IHCIHC analysis of EDEM3 using anti-EDEM3 antibody (A10297-2). EDEM3 was detected in a paraffin-embedded section of human liver cancer tissue.

HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000116406-EDEM3/tissue/cerebral+cortex#imid_6876856

HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000116406-EDEM3/tissue/colon#imid_6876486

HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000116406-EDEM3/tissue/liver#imid_6876487

HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000116406-EDEM3/tissue/kidney#imid_6876480

HPA ICC-IF BJ [Human fibroblast] — EDEM3 (HPA027297)

HPA · ICC-IF BJ [Human fibroblast]Human Protein Atlas immunofluorescence, BJ [Human fibroblast], antibody HPA027297; green = EDEM3, blue = nucleus, red = microtubules.

← swipe / scroll for more images →

Real IHC / IF data behind the staining-pattern expectations in this section.

Sample controls for EDEM3 IHC & IF

🧪Run adrenal gland first: glandular cells should stain (HPA: High in adrenal gland glandular cells). Run vagina as the negative tissue (HPA: Not detected in squamous epithelial cells); on the adrenal slide, non-glandular stromal cells should show only background as an internal check, though they are not a validated EDEM3-negative population.

Positive control tissue: Adrenal gland (Glandular cells, HPA High)

Negative control tissue: Vagina (HPA Not detected)

ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show EDEM3 in BJ [Human fibroblast], U-251MG, U2OS, ASC52telo, with annotated localisation: Endoplasmic reticulum (approved) (HPA subcellular).

Technical controls: Include no-primary (secondary-only) and matched nonimmune rabbit IgG controls, matching clonality and isotype where applicable (caption: rabbit primary antibody; standard IHC practice). Use EDEM3 knockout tissue as a biological negative if available, or an immunizing-peptide block if the peptide is available; assess endogenous peroxidase and biotin background in adrenal tissue because the demonstrated detection uses biotin, SABC and DAB (caption: detection method; standard IHC practice).

⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected A10297-2 paraffin-section caption does not state a fixative (caption: fixative unreported). The caption uses heat-mediated retrieval in EDTA at pH 8.0, but retrieval dependency is unreported; no supplied frozen-section evidence shows that frozen IHC is easier, and HPA ICC-IF images support an ER localization check without establishing that IF is easier (caption: EDTA retrieval; HPA: approved ER location and ICC-IF images). With the demonstrated biotin-SABC/DAB method, check adrenal sections for endogenous biotin and peroxidase background (caption: detection method; standard IHC practice).

HPA tissue IHC evidence for EDEM3

Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Medium consistency between antibody staining and RNA expression data. Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

Tissue	Cell type	Level	Evidence	Source
Adrenal gland	Glandular cells	High	Protein (IHC)	HPA →
Cerebral cortex	Neuronal cells	High	Protein (IHC)	HPA →
Heart muscle	Cardiomyocytes	High	Protein (IHC)	HPA →
Parathyroid gland	Glandular cells	High	Protein (IHC)	HPA →
Skeletal muscle	Myocytes	High	Protein (IHC)	HPA →

Undetected expression · recommended negative controls

Tissue	Cell type	Level	Evidence	Source
Vagina	Squamous epithelial cells	Not detected	Protein (IHC)	HPA →

Section 3

Advanced EDEM3 IHC Tips

Troubleshoot EDEM3 staining in paraffin section IHC using the catalog antibody’s tissue example, expected ER localisation, and appropriate controls.

Which retrieval condition should I try first for EDEM3 paraffin section IHC?

Start with heat mediated retrieval in EDTA at pH 8.0 (datasheet A10297-2). The catalog antibody’s paraffin section example used that condition before incubation at 2 μg/ml overnight at 4°C (caption A10297-2). If staining is weak, compare a cautiously adjusted heat retrieval duration on matched sections while holding antibody concentration and detection constant (standard IHC practice). Include a section processed without primary antibody to distinguish retrieval related background from specific staining (standard IHC practice). Judge improvement by cellular staining consistent with the ER, rather than a general increase in DAB intensity (UniProt Q9BZQ6 subcellular location; standard IHC practice).

How should I handle uncertain fixation when EDEM3 staining is weak?

The catalog image documents a paraffin embedded section, but its caption does not state the fixative (caption A10297-2). Target specific fixation sensitivity is therefore unknown; do not infer it from tissue expression patterns or EDEM3’s topology (caption A10297-2; HPA tissue IHC; UniProt Q9BZQ6 topology). Record the fixative and fixation duration for each specimen, then compare matched sections using the same EDTA pH 8.0 retrieval and detection workflow (datasheet A10297-2; standard IHC practice). If processing differs between cases, assess staining alongside tissue morphology and a consistently processed control before assigning biological meaning to intensity differences (standard IHC practice).

What staining pattern fits EDEM3, and which patterns should prompt review?

EDEM3 is assigned to the ER lumen, with no transmembrane segment (UniProt Q9BZQ6 subcellular location and topology). In chromogenic sections, expect cytoplasmic staining compatible with an ER distribution, although DAB resolution may not reveal a fine reticular pattern (HPA tissue IHC: cytoplasmic expression in most tissues; standard IHC practice). Predominantly nuclear, cell surface, or extracellular DAB should prompt review of morphology, background, and primary omission controls before calling it EDEM3 (UniProt Q9BZQ6 subcellular location; standard IHC practice). Compare the suspected compartment across intact cells and the matched control rather than treating every brown deposit within a tissue region as positive (standard IHC practice).

How do processing and isoforms affect interpretation of an EDEM3 epitope?

EDEM3 has 2 annotated isoforms, a signal sequence at residues 1–41, and a processed chain spanning residues 42–932 (UniProt Q9BZQ6 isoforms and processing). Its annotated glycosylation sites include residues 118, 195, 504, 511, 810, 814, and 900, and its PA domain spans 674–779 (UniProt Q9BZQ6 glycosylation and domains). The supplied antibody evidence does not identify the recognized epitope or establish isoform coverage (caption A10297-2). Check the antibody’s epitope documentation before interpreting absent staining as loss of both isoforms, and compare matched retrieval conditions if accessibility is in question (standard IHC practice).

How can I check EDEM3 localisation with multiplex immunofluorescence?

Use IF as a separate assay and check for signal consistent with EDEM3’s approved ER localisation (HPA subcellular: endoplasmic reticulum; UniProt Q9BZQ6 subcellular location). Multiplex with a validated marker for the cell type being evaluated, selecting spectrally separated fluorophores and a channel with low tissue autofluorescence for the weaker signal (standard IF practice). Because EDEM3 is luminal and lacks a transmembrane segment, choose permeabilisation that gives antibody access inside the ER, then optimise it against cell preservation (UniProt Q9BZQ6 topology and subcellular location; standard IF practice). Include single stain and no primary controls to check bleed through and autofluorescence before comparing IF with chromogenic IHC (standard IF practice).

How should I reduce diffuse brown staining without losing EDEM3 signal?

First inspect a no primary control to separate detection background from antibody dependent staining (standard IHC practice). The documented chromogenic example used 10% goat serum blocking, a biotinylated secondary, streptavidin biotin detection, and DAB (caption A10297-2). In a comparable workflow, check peroxidase blocking and evaluate whether endogenous biotin or nonspecific secondary binding contributes to signal; these are general IHC controls, not demonstrated EDEM3 effects (standard IHC practice). Keep retrieval at EDTA pH 8.0 initially and adjust blocking, washing, or detection on matched sections while monitoring preserved cytoplasmic staining (datasheet A10297-2; HPA tissue IHC; standard IHC practice).

What should I score when comparing EDEM3 across paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION

Score EDEM3 in a prespecified cell population using the percentage of positive cells and staining intensity, or combine these as an H-score from 0–300 (standard IHC practice). Restrict scoring to viable, morphologically identifiable cells and record cytoplasmic signal separately from misplaced or diffuse DAB (HPA tissue IHC: cytoplasmic expression in most tissues; standard IHC practice). Normalise cell counts to the number of eligible cells, or positive cell density to sampled tissue area in mm², and apply the same threshold across sections (standard IHC practice). Compare cases only after documenting section processing, retrieval, staining batch, and control performance (standard IHC practice).

When is an apparent EDEM3 positive result likely to be artefactual?

A credible result places signal in intact cell cytoplasm consistent with an ER luminal protein (UniProt Q9BZQ6 subcellular location; HPA tissue IHC: cytoplasmic expression in most tissues). HPA reports high staining in several cell populations, including stomach glandular cells, and no detected staining in vaginal squamous epithelial cells; these patterns can guide comparison but do not validate an individual section (HPA tissue IHC). Treat dominant nuclear or extracellular staining, tissue edge enhancement, and staining over necrosis as reasons to review the call (UniProt Q9BZQ6 subcellular location; standard IHC practice). Use morphology and no primary controls to investigate endogenous enzyme activity or detection deposits before assigning those signals to EDEM3 (standard IHC practice).

Boster reagents

Best EDEM3 / ER degradation-enhancing alpha-mannosidase-like protein 3 IHC Antibodies

A10297-2 has IHC images from paraffin sections of human appendiceal adenocarcinoma and liver cancer; no IF image is supplied (catalog: A10297-2 image captions).

Real IHC data

Anti-EDEM3 Antibody ®

Cat # A10297-2

View product →

A10297-2 is listed for human IHC and has an image from a paraffin section of appendiceal adenocarcinoma (catalog: A10297-2 applications and reactivity; IHC caption). A second IHC image shows a paraffin section of human liver cancer (catalog: A10297-2 IHC caption).

Which to pick: Choose A10297-2 for human tissue IHC: it is a rabbit polyclonal antibody listed for IHC, with a suggested concentration of 2–5 μg/ml (catalog: A10297-2 applications, reactivity, clonality and dilution). Its IHC captions describe paraffin sections, EDTA retrieval at pH 8.0 and primary antibody at 2 μg/ml; the fixative is unreported (catalog: A10297-2 IHC captions). No SKU in this payload is listed for IF/ICC or species other than human (catalog: A10297-2 applications and reactivity).

Each figure is that product's own IHC / IF validation image from its datasheet.

References

UniProt Consortium. UniProt entry Q9BZQ6 (EDEM3_HUMAN, ER degradation-enhancing alpha-mannosidase-like protein 3).
Human Protein Atlas. EDEM3 tissue IHC expression (reliability: Approved).
Human Protein Atlas. EDEM3 subcellular location (ICC-IF): Localized to the endoplasmic reticulum..
Human Protein Atlas. EDEM3 antibody validation summary (3 antibodies).
miR-379 mediates insulin resistance and obesity through impaired angiogenesis and adipogenesis regulated by ER stress. Molecular therapy. Nucleic acids 2022 — PMC9535382.
miR-379 deletion ameliorates features of diabetic kidney disease by enhancing adaptive mitophagy via FIS1. Communications biology 2021 — PMC7782535.
PubMed PMID:14702039 — UniProt-cited evidence.
PubMed PMID:16710414 — UniProt-cited evidence.
PubMed PMID:15489334 — UniProt-cited evidence.